CANbridge Acquires Rights to Gene Therapy Candidates

CANbridge Acquires Rights to Gene Therapy Candidates

293824

CANbridge Acquires Rights to Gene Therapy Candidates

CANbridge Pharmaceuticals has entered a strategic collaboration and license agreement to gain global rights to LogicBio Therapeutics’ gene therapy candidates for rare diseases with limited treatment options. Under the agreement, CANbridge now owns worldwide rights to develop, manufacture, and commercialize gene therapy candidates for Fabry disease and Pompe disease, as well as the option to advance two additional gene therapy programs for undisclosed indications. LogicBio also granted CANbridge the option to license a gene-editing technology, LB-001, for…

You must be logged in to read/download the full post.